Yuhan Corporation Stock price

Equities

A000100

KR7000100008

Pharmaceuticals

End-of-day quote Korea S.E. 06:00:00 2024-02-28 pm EST 5-day change 1st Jan Change
67,400 KRW -1.89% Intraday chart for Yuhan Corporation +2.43% -2.03%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
Sales 2023 1,859B 1.39B Sales 2024 * 2,086B 1.56B Capitalization 5,123B 3.84B
Net income 2023 143B 107M Net income 2024 * 182B 136M EV / Sales 2023 2.77 x
Net cash position 2023 * 188B 141M Net cash position 2024 * 330B 247M EV / Sales 2024 * 2.3 x
P/E ratio 2023 *
54.7 x
P/E ratio 2024 *
33.1 x
Employees 1,999
Yield 2023 *
0.54%
Yield 2024 *
0.55%
Free-Float 63.86%
More Fundamentals * Assessed data
Dynamic Chart
Progen Co., Ltd. announced that it has received KRW 9.71405799 billion in funding from Yuhan Corporation and other investors CI
COSON Co., Ltd. announced that it expects to receive KRW 3 billion in funding from Cruise Holdings Co., Ltd., Yuhan Corporation and other investors. CI
Yuhan Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Yuhan Corporation completed the acquisition of 42% stake in ImmuneOncia Therapeutics Inc. from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for $20 million. CI
Contagion fears spread as China property sector cash crunch intensifies RE
Yuhan Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Country Garden shares dive after bond trading halted, fans further economic distress RE
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2024. CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2024. CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2024. CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2024. CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2024. CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2024. CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2024. CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2024. CI
More news
1 day-1.01%
1 week+4.41%
Current month+16.05%
1 month+11.89%
3 months+14.86%
6 months+0.19%
Current year-0.15%
More quotes
1 week
64 200.00
Extreme 64200
71 200.00
1 month
57 500.00
Extreme 57500
71 200.00
Current year
57 500.00
Extreme 57500
71 200.00
1 year
47 571.43
Extreme 47571.4286
84 190.48
3 years
47 571.43
Extreme 47571.4286
84 190.48
5 years
30 851.34
Extreme 30851.3428
84 190.48
10 years
21 997.28
Extreme 21997.2793
84 190.48
More quotes
Managers TitleAgeSince
Chief Executive Officer 69 87-04-30
Chairman 72 78-04-30
Director/Board Member 66 -
Members of the board TitleAgeSince
Chairman 72 78-04-30
Chief Executive Officer 69 87-04-30
Director/Board Member 66 -
More insiders
Date Price Change Volume
24-02-28 67,400 -1.89% 406 058
24-02-28 68,700 -1.01% 322,926
24-02-27 69,400 -0.72% 583,786
24-02-26 69,900 +4.33% 1,168,985
24-02-23 67,000 +4.20% 1,157,150

End-of-day quote Korea S.E., February 27, 2024

More quotes
Yuhan Corporation is a Korea-based company mainly engaged in the manufacture and sale of pharmaceuticals. Along with its subsidiaries, the Company operates its business through three segments. The Pharmaceutical segment is engaged in the production and sale of non-prescription drugs including anti-inflammatory drugs, as well as prescription drugs such as drugs for hepatitis, diabetes, and hypertension. The Life and Health segment is involved in the production and sale of household goods and animal healthcare (AHC) products, including bleach, antibacterial agents. The Overseas Business segment supplies raw drugs which manufactured by Yuhan Chemical Inc. to domestic and overseas markets. The Company distributes its products within the domestic market and to overseas markets, including Europe, Asia and United States.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
68,700 KRW
Average target price
82,400 KRW
Spread / Average Target
+19.94%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Yuhan Corporation - Korea S.E.
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW